Nicholas D. P. Cosford
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicholas D. P. Cosford has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Gautam Borthakur
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
19 shared publications - Hagop M. Kantarjian
Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA
19 shared publications - Huaxian Ma
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
19 shared publications - Marina Konopleva
Albert Einstein College of Medicine
19 shared publications - Michael Andreeff
Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
19 shared publications - Natalia Baran
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
19 shared publications
Latest Publications
- Open Access
Reversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase
Fatty acid synthase (FASN) is the sole enzyme capable of lipogenesis in cells and is upregulated in many cancers. Herein we report the discovery and development of SBP-5917 ( 78S ), a novel, reversible, small-molecule probe which targets the thioesterase (TE) domain of FASN. SBP-5917 and other compounds in the series possess IC 50 < 1 µM and < 5 µM for inhibiting recombinantly purified FASN-TE and cellular FASN respectively. Co-crystal structures of our inhibitors bound to the FASN-TE domain show that they are positioned in the substrate tunnel of the enzyme. Biochemical and biophysical analyses quantify the strength of compound binding and demonstrate their selectivity for FASN-TE. Preliminary pharmacokinetic studies indicate promising in vivo potency for many of the compounds in the series. SBP-5917 is the first structurally validated, reversible inhibitor of FASN-TE with demonstrated cellular target engagement and can serve as a chemical probe to investigate FASN as a therapeutic target. ABSTRACT FIGURE:
Open AccessReversible, Orally Bioavailable Small-Molecule Inhibitors Occupy the Substrate Tunnel of the Thioesterase Domain of Fatty Acid Synthase
Fatty acid synthase (FASN) is the sole enzyme capable of lipogenesis in cells and is upregulated in many cancers. Herein we report the discovery and development of SBP-5917 ( 78S ), a novel, reversible, small-molecule probe which targets the thioesterase (TE) domain of FASN. SBP-5917 and other compounds in the series possess IC 50 < 1 µM and < 5 µM for inhibiting recombinantly purified FASN-TE and cellular FASN respectively. Co-crystal structures of our inhibitors bound to the FASN-TE domain show that they are positioned in the substrate tunnel of the enzyme. Biochemical and biophysical analyses quantify the strength of compound binding and demonstrate their selectivity for FASN-TE. Preliminary pharmacokinetic studies indicate promising in vivo potency for many of the compounds in the series. SBP-5917 is the first structurally validated, reversible inhibitor of FASN-TE with demonstrated cellular target engagement and can serve as a chemical probe to investigate FASN as a therapeutic target. ABSTRACT FIGURE:
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.
- Open Access
- 16 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques
Despite the success of antiretroviral therapy in controlling HIV replication, latent viral reservoirs persist, presenting a major barrier to a cure. Current treatment approaches that aim to reactivate latent virus and eliminate infected cells, termed “shock and kill,” hold promise but have yet to demonstrate meaningful reservoir reduction in vivo. In this study, we explored combining ciapavir, a Smac mimetic latency-reversing agent, with adeno-associated virus–delivered (AAV-delivered) eCD4-Ig to treat antiretroviral therapy–suppressed, SHIV-infected rhesus macaques. We could demonstrate that a Smac mimetic can induce modest reactivation of the latent SHIV reservoir, as evidenced by transient increases in plasma viremia. However, while AAV-expressed eCD4-Ig conferred partial protection against intrarectal SHIV challenge in uninfected animals, neither eCD4-Ig nor ciapavir reduced the viral reservoir in SHIV-infected rhesus macaques, as determined by total SHIV DNA and a 5-target intact provirus detection assay. Animals treated with the combination showed no significant differences in viral rebound kinetics post–analytical treatment interruption compared with controls. Additionally, repeated ciapavir dosing resulted in adverse effects in some animals, suggesting potential toxicity with repeat administration. These findings highlight the challenges in reducing viral reservoirs using this shock-and-kill approach, particularly in SHIV-infected models, and suggest that further optimization of both latency-reversing agent and immune-mediated clearance strategies is required.
- 16 March 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (6)
Open AccessSmac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques
Despite the success of antiretroviral therapy in controlling HIV replication, latent viral reservoirs persist, presenting a major barrier to a cure. Current treatment approaches that aim to reactivate latent virus and eliminate infected cells, termed “shock and kill,” hold promise but have yet to demonstrate meaningful reservoir reduction in vivo. In this study, we explored combining ciapavir, a Smac mimetic latency-reversing agent, with adeno-associated virus–delivered (AAV-delivered) eCD4-Ig to treat antiretroviral therapy–suppressed, SHIV-infected rhesus macaques. We could demonstrate that a Smac mimetic can induce modest reactivation of the latent SHIV reservoir, as evidenced by transient increases in plasma viremia. However, while AAV-expressed eCD4-Ig conferred partial protection against intrarectal SHIV challenge in uninfected animals, neither eCD4-Ig nor ciapavir reduced the viral reservoir in SHIV-infected rhesus macaques, as determined by total SHIV DNA and a 5-target intact provirus detection assay. Animals treated with the combination showed no significant differences in viral rebound kinetics post–analytical treatment interruption compared with controls. Additionally, repeated ciapavir dosing resulted in adverse effects in some animals, suggesting potential toxicity with repeat administration. These findings highlight the challenges in reducing viral reservoirs using this shock-and-kill approach, particularly in SHIV-infected models, and suggest that further optimization of both latency-reversing agent and immune-mediated clearance strategies is required.
- 12 February 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (3) , 469-489
Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer
Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including nonsmall cell lung cancer (NSCLC). We previously reported SBP-7455, a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2 and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501, two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, either as a single agent or in combination with current therapies.
- 12 February 2026
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 21 (3) , 469-489
Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer
Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including nonsmall cell lung cancer (NSCLC). We previously reported SBP-7455, a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2 and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501, two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, either as a single agent or in combination with current therapies.
- Open Access
ULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers
KRAS mutations drive tumorigenesis in multiple cancer types, including lung and pancreatic cancer. Autophagy is a cell survival pathway that supports tumor growth under metabolic stress and has been proposed to be a potential therapeutic avenue specifically in KRAS mutant cancers. The Unc-51-like ATG-activating kinases 1 and 2 (ULK) initiate the earliest regulated steps of autophagy and are the only protein kinases in the canonical autophagy pathway, thus making them attractive therapeutic targets for KRAS mutant tumors. We show here that genetic depletion of ULK1 or ATG13, core components of the ULK1 complex, in KRAS mutant lung and pancreatic cancer cell lines results in growth inhibition. Previously, we developed small molecule ULK1 inhibitors that not only inhibit ULK kinase activity but also induced the degradation of other core members of the ULK complex including ATG101 and ATG13. Therefore, we developed a high-throughput screening (HTS) assay in which ATG13 was HiBiT-tagged in KRAS mutant lung cancer cells to evaluate ULK inhibitors for ATG13 degradation. Using this approach, we discovered a lead ULK inhibitor, SBP-1750 , that potently inhibited ULK activity, promoted robust ATG13 degradation, impaired ATG, and induced KRAS mutant cancer cell death. Studies in a KRAS-mutant orthotopic syngeneic pancreatic cancer model show that oral treatment with SBP-1750 significantly reduced tumor growth. Pharmacokinetic analysis of SBP-1750 indicates favorable drug exposure and pharmacodynamic analysis confirms ATG13 degradation in vivo, mirroring in vitro results. Finally, immunohistochemical staining of orthotopic pancreatic tumors reveals a significant increase in CD4⁺ and CD8⁺ T cell infiltration upon treatment, suggesting that SBP-1750 enhances anti-tumor immunity. These findings support further development of SBP-1750 as a novel ATG-targeting cancer therapy.
Open AccessULK1/2 Inhibitors that Degrade ATG13 Effectively Target KRAS-Mutant Cancers
KRAS mutations drive tumorigenesis in multiple cancer types, including lung and pancreatic cancer. Autophagy is a cell survival pathway that supports tumor growth under metabolic stress and has been proposed to be a potential therapeutic avenue specifically in KRAS mutant cancers. The Unc-51-like ATG-activating kinases 1 and 2 (ULK) initiate the earliest regulated steps of autophagy and are the only protein kinases in the canonical autophagy pathway, thus making them attractive therapeutic targets for KRAS mutant tumors. We show here that genetic depletion of ULK1 or ATG13, core components of the ULK1 complex, in KRAS mutant lung and pancreatic cancer cell lines results in growth inhibition. Previously, we developed small molecule ULK1 inhibitors that not only inhibit ULK kinase activity but also induced the degradation of other core members of the ULK complex including ATG101 and ATG13. Therefore, we developed a high-throughput screening (HTS) assay in which ATG13 was HiBiT-tagged in KRAS mutant lung cancer cells to evaluate ULK inhibitors for ATG13 degradation. Using this approach, we discovered a lead ULK inhibitor, SBP-1750 , that potently inhibited ULK activity, promoted robust ATG13 degradation, impaired ATG, and induced KRAS mutant cancer cell death. Studies in a KRAS-mutant orthotopic syngeneic pancreatic cancer model show that oral treatment with SBP-1750 significantly reduced tumor growth. Pharmacokinetic analysis of SBP-1750 indicates favorable drug exposure and pharmacodynamic analysis confirms ATG13 degradation in vivo, mirroring in vitro results. Finally, immunohistochemical staining of orthotopic pancreatic tumors reveals a significant increase in CD4⁺ and CD8⁺ T cell infiltration upon treatment, suggesting that SBP-1750 enhances anti-tumor immunity. These findings support further development of SBP-1750 as a novel ATG-targeting cancer therapy.
- Open Access
Synthesis and Characterization of ULK1/2 Kinase Inhibitors that Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer
Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including non-small cell lung cancer (NSCLC). We previously reported SBP-7455 , a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2, and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501 , two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, both as a single agent as well as in combination with current therapies.
Open AccessSynthesis and Characterization of ULK1/2 Kinase Inhibitors that Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer
Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including non-small cell lung cancer (NSCLC). We previously reported SBP-7455 , a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2, and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501 , two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, both as a single agent as well as in combination with current therapies.
- Open Access
- 31 January 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (5) , 4912-4926
Fragment Screening Identifies Novel Allosteric Binders and Binding Sites in the VHR (DUSP3) Phosphatase
The human Vaccinia H1-related phosphatase (VHR; DUSP3) is a critical positive regulator of the innate immune response. Recent studies suggest that inhibiting VHR could be beneficial in treating sepsis and septic shock. VHR belongs to the superfamily of protein tyrosine phosphatases (PTPs), a large class of enzymes that are notoriously difficult to target with small molecules. Fragment-based drug discovery (FBDD) has emerged as an effective strategy for generating potent ligands, even for challenging drug targets. Here, we present a fluorine NMR-based discovery platform for identifying fragments that bind to VHR. This platform encompasses automated library assembly, mixture formation, quantitative material transfer, fluorine NMR screening, and biophysical hit confirmation. We demonstrate that this streamlined, integrated screening workflow produces validated hits with diverse chemical matter and tangible structure-activity relationships (SAR). Crystal structures yielded detailed information on the fragment-protein interactions and provide a basis for future structurally enabled ligand optimization. Notably, we discovered novel ligand binding sites on VHR, distant from the conserved active site, facilitating the generation of selective VHR modulators. This fragment discovery platform can be applied to other PTPs and holds significant potential for identifying potent and selective ligands.
- 31 January 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (5) , 4912-4926
Open AccessFragment Screening Identifies Novel Allosteric Binders and Binding Sites in the VHR (DUSP3) Phosphatase
The human Vaccinia H1-related phosphatase (VHR; DUSP3) is a critical positive regulator of the innate immune response. Recent studies suggest that inhibiting VHR could be beneficial in treating sepsis and septic shock. VHR belongs to the superfamily of protein tyrosine phosphatases (PTPs), a large class of enzymes that are notoriously difficult to target with small molecules. Fragment-based drug discovery (FBDD) has emerged as an effective strategy for generating potent ligands, even for challenging drug targets. Here, we present a fluorine NMR-based discovery platform for identifying fragments that bind to VHR. This platform encompasses automated library assembly, mixture formation, quantitative material transfer, fluorine NMR screening, and biophysical hit confirmation. We demonstrate that this streamlined, integrated screening workflow produces validated hits with diverse chemical matter and tangible structure-activity relationships (SAR). Crystal structures yielded detailed information on the fragment-protein interactions and provide a basis for future structurally enabled ligand optimization. Notably, we discovered novel ligand binding sites on VHR, distant from the conserved active site, facilitating the generation of selective VHR modulators. This fragment discovery platform can be applied to other PTPs and holds significant potential for identifying potent and selective ligands.
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-9 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
Supplementary Table S1. Abbreviations of cell populations analyzed using Bloodspot.Supplementary Table S2. Comparative analysis of significance based on survival curves generated using GraphPad.Supplementary Table S3. Mutational profiles of AML cell lines and their sensitivity to SBI-0206965.Supplementary Table S4. Mutational profiles of AML patient derived primary samples.Supplementary Table S5. IC50 values of drug resistant cells.Supplementary Table S6. Combinatorial Index (CI-value) of combination treatments.Supplementary Table S7. Comparative analysis of significance based on survival curves generated using GraphPad (Ex vivo model).Supplementary Table S8. List of Antibodies.Supplementary Table S9. List of Primers.
- Open Access
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.
- 1 June 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
S1. Effect of genetic abrogation of ULK1 in vitro and in vivo.S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells.S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies.S4. ULK1 inhibition changes signaling in AML cells.S5. ULK1 inhibition hampers ROS.S6. ULK1 inhibition accumulates dysfunctional mitochondria.S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression.S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.